THE RISK OF DEVELOPING PROSTATE CANCER IS 20 PERCENT

Reading time is 2 mins

.
.
WHAT IS THE RISK OF DEVELOPING PROSTATE CANCER?

Turkey Medicals – hospital member Turkish Urologist Associate Doctor, said that a man has a lifetime risk of developing prostate cancer of about 20 percent.

Cancer is the second most common cause of death in the world after heart disease, says Urologist Assoc. Dr. “About 10 million deaths a year are caused by cancer. it has been found that from 2000 to the 2020s, cancer related death rates decreased by 26 percent. Prostate cancer is the most common type of cancer in men and accounts for about one in 4 of all cancer cases. A man has a lifetime risk of developing prostate cancer of around 20%. But only 3 percent of these patients lose their lives due to prostate cancer.”

This condition is associated with the diagnosis of prostate cancer, especially at an early stage, and the implementation of appropriate treatments. Contrary to what is known, prostate cancer does not give symptoms related to urination. But in advanced disease, there are pains associated with the spread of the disease. However, the treatments to be applied during this period may be aimed at improving the patient’s quality of life rather than treating the disease.
.

For this reason, it is extremely important to diagnose it at an early stage, when the disease is still limited to the prostate, that is, it has not spread to the body and does not cause symptoms. It is recommended that every man have a prostate examination with a urologist once a year after the age of 50.

.
A rectal finger examination of the prostate and measuring the level of an enzyme secreted from the prostate that we call PSA in the blood are the main methods used to diagnose Assoc. Dr. “If there is a suspicion of PSA height or finger examination findings, the final diagnosis is made by taking a sample of the prostate with a prostate biopsy and examining it. MRI fusion biopsies are the most current application. By detecting the focus of cancer in the prostate with an MRI image, it is synchronized with ultrasound and a sample of cancerous tissue can be taken directly under the guidance of ultrasound.

In this way, more reliable samples can be taken than standard biopsies, and cancer can be diagnosed at a higher rate and accurately. The choice of treatment for prostate cancer depends on the patient’s age, general condition, the prevalence of the disease and the nature of the tumor. If it was diagnosed at an early stage, the prostate and surrounding tissues can be completely removed surgically and completely cleared of cancer.

A second option is to destroy cancerous tissues by irradiating the entire prostate with radiotherapy. If the cancerous tissue is in a small focus, only the area where the cancerous tissue is located can be destroyed by using sound energy with focal treatments (HIFU).

While the course of cancer is observed with active monitoring in patients with low progression potential in a very small focus, options such as hormone therapy, drug therapy (chemotherapy) or follow-up can be applied in advanced stage cancers.
.

In treatment of prostate cancer in Turkey the patients and cancer-related characteristics, considering the expectations of the patient, the doctor, a joint decision by the patient and the patient’s family, will be the most accurate approach.

.
.
.
.

Follow me
President of Organ Transplant Center at MedicalPark Hospital Antalya

Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.

Physician's Resume:

Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.

Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.

In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.

Awards:

Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.

Certificates:

Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .

Professional Members:

American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.

Disclaimer:

Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.
Medically Reviewed by Professor Doctor Alper Demirbaş
Follow me